This article analyzes the clinical trial application process across Europe, the USA, and India, highlighting regulatory frameworks and documentation requirements.
Clinical trials serve as the cornerstone for advancing medical knowledge, ensuring patient safety, and enabling the approval of new therapies across the globe. However, the regulatory frameworks governing clinical trials vary significantly across regions, reflecting differences in healthcare systems, legal requirements, and regulatory authorities. This article provides an overview of clinical trials and the clinical trial application (CTA) process from a regulatory perspective in Europe, the United States, and India. It highlights the role of key regulatory bodies such as the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and the Central Drugs Standard Control Organization (CDSCO), and compares the processes, timelines, and documentation requirements across these jurisdictions. By examining both the similarities and unique aspects of each system, the article aims to provide a comprehensive understanding of the global clinical trial landscape and its implications for drug development and approval.
No takes yet. Share an insight, caveat, or question.
Akshatha et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: